

## Marc Ehlers

Ph.D., Professor of Immunology

Dr. Marc Ehlers (\*1966) is a specialist in Immunology with focus on allergy, autoimmunity, cancer, infection, vaccination and diet. He studied Biology and Chemistry and did his Dr. rer. nat. at the RWTH Aachen in 1997. Upon his Post-doc and group leader time at the Max-Planck Institute for Immunobiology in Freiburg from 1996 to 2002, he went during his Assistant Professor time at the University of Essen for 2 years to the Laboratory of Jeffrey Ravetch at The Rockefeller University in New York, USA. Back in Germany in 2005, he started as group leader at the German Rheumatism Research Center, an Institute of the Leibnitz Association, in Berlin. In 2010 he started as Professor at the University of Lübeck and is a co-founder of the Institute of Nutritional Medicine.

[marc.ehlers@uni-luebeck.de](mailto:marc.ehlers@uni-luebeck.de)  
[marc.ehlers@uksh.de](mailto:marc.ehlers@uksh.de)

### Publications:

ORCID (0000-0002-5383-8603) and Scopus (7102012162).

### Selected publications:

1. Dühning L, Petry J, Lilienthal G-M, Bartsch YC, Kubiak M, Pfeufer C, Lehrian S, Buhre JS, Lunding HB, Kern C, Behrends J, Walsemann T, Gädert L, Sommer C, Krüger L, Blanchard V, Dehmel S, Jappe U, Rahmüller J, Ehlers M. Sialylation of IgE reduces FcεR1α binding and mast cell activation in vitro and increases IgE half-live in vivo. *Allergy* 2023. doi: 10.1111/all.15665. Online ahead of print. PMID: 36724158.
2. Buhre JS, Pongracz T, Künsting I, Lixenfeld AS, Wang W, Nouta J, Lehrian S, Schmelter F, Lunding HB, Dühning L, Kern C, Petry J, Martin EL, Föh B, Steinhaus M, von Kopylow V, Sina C, Graf T, Rahmüller J, Wuhrer M, Ehlers M. mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine. *Front Immunol* 2023; 13:1020844. doi: 10.3389/fimmu.2022.1020844. PMID: 36713457.
3. Van Coillie J, Pongracz T, Rahmüller J, Chen H-J, Geyer C, van Vught LA, Buhre JS, Šuštić T, van Osch TJJ, Steenhuis M, Hoepel W, Wang W, Lixenfeld AS, Nouta J, Keijzer S, Linty F, Visser R, Larsen MD, Martin EL, Künsting I, Lehrian S, von Kopylow V, Kern C, Lunding HB, de Winther M, van Mourik N, Rispens T, Graf T, Slim MA, Minnaar R, Bomers MK, Sikkens JJ, Vlaar APJ, van der Schoot CE, den Dunnen J, Wuhrer M, Ehlers M, Vidarsson G, in collaboration with the Fatebenefratelli-Sacco Infectious Diseases Physicians group and UMC COVID-19 S3/HCW study group. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccines. *eBioMedicine* 2023; 87:104408. doi: 10.1016/j.ebiom.2022.104408. PMID: 36529104.
4. Bieber K, Hundt JE, Yu X, Ehlers M, Petersen F, Karsten CM, Köhl J, Kridin K, Kalies K, Kasprick A, Goletz S, Humrich J, Manz RA, Künstner A, Hammers CH, Akbarzadeh R, Busch H, Sadik CD, Lange T, Grasshoff H, Hackel AM, Erdmann J, König I, Raasch W, Becker M, Kerstein-Stähle A, Lamprecht P, Riemekasten G, Schmidt E, Ludwig RJ. Autoimmune pre-disease. *Autoimmunity Reviews* 2023, 22(2), 103236; doi: 10.1016/j.autrev.2022.103236. PMID: 36436750.
5. Thiessen H, Käding N, Gebel B, Borsche M, Graspentner S, Kirchhoff L, Ehlers M, Rahmölle J, Taube S, Kramer J, Klein C, Katalinic A, Rupp J. Risk assessment of SARS-CoV-2 transmission in hospitality employees in a highly frequented tourist area. *Heliyon* 2022, 8(12), e12177. doi: 10.1016/j.heliyon.2022.e12177.

6. Föh B, Buhre JS, Sina C, Ehlers M. Influence of nutrients and metabolites on the differentiation of plasma cells and implications for autoimmunity. *Front Immunol* 2022; 13:1004644. doi: 10.3389/fimmu.2022.1004644. PMID: 36466846.
7. Buhre JS, Becker M, Ehlers M. IgG subclass and Fc glycosylation shifts are linked to the transition from pre-to inflammatory autoimmune conditions. *Front Immunol* 2022; 13:1006939. doi: 10.3389/fimmu.2022.1006939. PMID: 36405742.
8. Albrecht M, Schaub B, Gilles S, Köhl J, Altrichter S, Voehringer D, Spillner E, Ehlers M, Jönsson F, Loser K, Mayer JU, Rösner LM, Möbs C, Heine G, Pfützner W. Current research and unmet needs in allergy and immunology in Germany: report presented by the DGfI and DGAKI task force Allergy & Immunology. *Eur J Immunol* 2022; 52(6):851-855. doi: 10.1002/eji.202270065. PMID: 35654759.
9. Balck A, Föh B, Borsche M, Rahmöller J, Vollstedt EJ, Waldeck F, Käding N, Twesten C, Mischnik A, Gillissen-Kaesbach G, Ehlers M, Sina C, Taube S, Busch H, Rupp J, Katalinic A, Klein C. Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study. *BMC Public Health* 2022; 22(1):1305. doi: 10.1186/s12889-022-13666-z. PMID: 35799167.
10. Klein C, Borsche M, Balck A, Föh B, Rahmöller J, Peters E, Knickmann J, Lane M, Vollstedt EJ, Elsner SA, Käding N, Hauswaldt S, Lange T, Hundt JE, Lehrian S, Giese J, Mischnik A, Niemann S, Maurer F, Homolka S, Paulowski L, Kramer J, Twesten C, Sina C, Gillissen-Kaesbach G, Busch H, Ehlers M, Taube S, Rupp J, Katalinic A. One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk. *Sci Adv* 2022; 8(15):eabm5016. doi: 10.1126/sciadv.abm5016. PMID: 35427158.
11. Föh B, Buhre JS, Lunding HB, Moreno-Fernandez ME, König P, Sina C, Divanovic S, and Ehlers M. Microbial metabolite butyrate promotes induction of IL-10+IgM+ plasma cells. *PLoS One* 2022; 17(3):e0266071. doi: 10.1371/journal.pone.0266071. PMID: 35333906.
12. Nogueira Almeida L, Clauder AK, Meng L, Ehlers M, Arce S, Manz RA. MHC haplotype and B cell autoimmunity: Correlation with pathogenic IgG autoantibody subclasses and Fc glycosylation patterns. *Eur J Immunol* 2022; 52(2):197-203. doi: 10.1002/eji.202149279. PMID: 34609741.
13. Borsche M, Reichel D, Fellbrich A, Lixenfeld AS, Rahmöller J, Vollstedt EJ, Föh B, Balck A, Klein C, Ehlers M, Moser A. Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19. *Neurol Res Pract* 2021; 3(1):34. doi: 10.1186/s42466-021-00135-y. PMID: 34148546.
14. Schmelter F, Föh B, Mallagaray A, Rahmöller J, Ehlers M, Lehrian S, von Kopylow V, Künsting I, Lixenfeld AS, Martin E, Ragab M, Meyer-Saraei R, Kreutzmann F, Eitel I, Taube S, Käding N, Jantzen E, Graf T, Sina C, Günther UL. Metabolic and lipidomic markers differentiate COVID-19 from non-hospitalized and other intensive care patients. *Front Mol Biosci* 2021; 8:737039. doi: 10.3389/fmolb.2021.737039. PMID: 34938772.
15. Lixenfeld AS, Künsting I, Martin EL, von Kopylow V, Lehrian S, Lunding HB, Buhre JS, Quack J, Steinhaus M, Graf T, Ehlers M, Rahmöller J. The BioNTech / Pfizer vaccine BNT162b2 induces class-switched SARS-CoV-2-specific plasma cells and potential memory B cells as well as IgG and IgA serum and IgG saliva antibodies upon the first immunization. *MedRxiv* 2021. 2021.03.10.21252001. doi: 10.1101/2021.03.10.21252001.
16. Clauder A-K, Kordowski A, Bartsch YC, Köhl G, Lilienthal G-M, Almeida LN, Lindemann T, Petry J, Rau CN, Gramalla-Schmitz A, Dühring L, Elbracht C, Kenno S, Tillmann J, Wuhrer M, Ludwig R, Ibrahim SM, Bieber K, Köhl J, Ehlers M, and Manz R. IgG Fc N-glycosylation translates MHCII haplotype into autoimmune skin disease. *J Invest Dermatology* 2021; 141(2):285-294. doi: 10.1016/j.jid.2020.06.022. PMID: 32653301.

17. Petry J, Rahmüller J, Dühning L, Lilienthal G-M, Lehrian S, Buhre JS, Bartsch YC, Epp A, Lunding H, Moremen KW, Leliavski A, and Ehlers M. Enriched blood IgG sialylation attenuates IgG-mediated and IgG-controlled-IgE-mediated allergic reactions.

J Allergy Clin Immunol. 2021; 147(2):763-767. doi: 10.1016/j.jaci.2020.05.056. PMID: 32603664.

18. Bartsch YC, Eschweiler S, Leliavski A, Lunding H, Wagt S, Petry J, Lilienthal G-M, Rahmüller J, de Haan N, Hölscher A, Erapanedi R, Giannou AD, Aly L, Sato R, de Neef LA, Winkler A, Braumann D, Hobusch J, Kuhnigk K, Krémer V, Steinhaus M, Blanchard V, Gemoll T, Habermann J, Collin M, Salinas-Riesters G, Manz R, Korn T, Fukuyama H, Waisman A, Yogeve N, Huber S, Rabe B, Rose-John S, Busch H, Berberich-Siebelt F, Hölscher C, Wuhrer M, and Ehlers M. IgG Fc sialylation is regulated during the germinal center reaction upon immunization with different adjuvants.

J Allergy Clin Immunol 2020; 146(3):652-666. doi: 10.1016/j.jaci.2020.04.059. PMID: 32445838.

19. Vorobyev A, Gupta Y, Sezin T, Koga H, Bartsch YC, Belheouane M, Künzel S, Sina C, Schilf P, Körber-Ahrens H, Beltsiou F, Ernst A, Khil'chenko S, Al-Aasam H, Manz R, Diehl S, Steinhaus M, Jascholt J, Kouki P, Boehncke W-H, Mayadas T, Zillikens D, Sadik C, Nishi H, Ehlers M, Möller S, Bieber K, Baines J, Ibrahim S, and Ludwig R. Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line. Nat Commun 2019; 10(1):4097. PMID: 31506438.

20. Twisselmann N, Bartsch YC, Pagel J, Wieg C, Hartz A, Ehlers M, and Härtel C. IgG Fc glycosylation patterns of preterm infants differ with gestational age.

Frontiers Immunol 2019; 9:03166. doi: 10.3389/fimmu.2018.03166. PMID: 30713537.

21. Bartsch Y, Rahmüller J, Mertes MMM, Eglmeier S, Lorenz FKM, Stoehr AD, Braumann D, Lorenz AK, Winkler A, Lilienthal G-M, Petry J, Hobusch J, Steinhaus M, Hess C, Holeccka V, Schoen CT, Oefner CM, Leliavski A, Blanchard V, and Ehlers M. Sialylated autoantigen-reactive IgG antibodies attenuate disease development in autoimmune mouse models of lupus nephritis and rheumatoid arthritis.

Frontiers Immunol. 2018; 9:1183. doi: 10.3389/fimmu.2018.01183. PMID: 29928274.

22. Lilienthal G-M, Rahmüller J, Petry J, Bartsch YC, Leliavsky A, and Ehlers M. Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fcγ receptor activation pathways.

Frontiers Immunol. 2018; 9:958. Perspective. doi: 10.3389/fimmu.2018.00958. PMID: 29867943.

23. Lamprecht P, Anja Kerstein A, Sebastian Klapa S, Schinke S, Karsten CM, Yu X, Ehlers M, Epplen J, Holl-Ulrich K, Thorsten Wiech T, Kalies K, Lange T, Laudien M, Laskay T, Gemoll T, Schumacher U, Ullrich S, Busch H, Ibrahim S, Fischer N, Hasselbacher K, Pries R, Petersen F, Weppner G, Manz RA, Humrich JY, Nieberding R, Riemekasten G, and Mueller A. Pathogenetic and clinical aspects of ANCA-associated vasculitides.

Frontiers Immunol. 2018; 9:680. Review. doi.org/10.3389/fimmu.2018.00680. PMID: 29686675.

24. Epp A, Hobusch J, Bartsch YC, Petry J, Lilienthal G-M, Koeleman CAM, Eschweiler S, Möbs C, Hall A, Morris SC, Petzold D, Engellenner C, Bitterling J, Rahmüller J, Leliavski A, Thurmann R, Collin M, Moremen KW, Strait RT, Blanchard V, Petersen A, Gemoll T, Habermann JK, Petersen F, Nandy A, Kahlert H, Hertl M, Wuhrer M, Pfützner W, Jappe U, Finkelman FD, and Ehlers M. Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions.

J Allergy Clin Immunol 2018; 141 (1): 399-402.e8. doi:10.1016/j.jaci.2017.06.021. PMID: 28728998.

25. Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, Weiss K-H, Liaskou E, Vesterhus M, Karlsen TH, Mindorf S, Schemmer P, Bär F, Teegen B, Schröder T, Ehlers M, Hammers CM, Komorowski L, Lehnert H, Fellermann K, Derer S, Hov JR, and Sina C. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.

Gut 2017; 66(1):137-144. doi: 10.1136/gutjnl-2016-311739. PMID: 27406039.

26. Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C, Herzel H, Tsang AH, Kawakami N, Leliavski A, Uhl O, Yao L, Sander LE, Chen C-S, Kraus K, de Juan A, Hergenhan SM, Ehlers M, Koletzko B, Haas R, Solbach W, Oster H, and Scheiermann C. Lymphocyte circadian clocks control lymph node trafficking and adaptive immune responses. *Immunity* 2017; 46(1):120-132. doi: 10.1016/j.immuni.2016.12.011. PMID: 28087238.
27. Strait RT, Posgai MT, Mahler A, Barasa N, Jacob CO, Köhl J, Ehlers M, Stringer K, Shanmukappa SK, Witte D, Hossain MM, Khodoun M, Herr AB, and Finkelman FD. IgG1 protects against renal disease in a mouse model of cryoglobulinemia. *Nature* 2015; 517(7535):501-504. doi: 10.1038/nature13868. PMID: 25363774. Erratum: *Nature* 2015; 526(7575): 728.
28. Schwedler C, Kaup M, Petzold D, Hoppe B, Braicu EI, Sehouli J, Ehlers M, Berger M, Tauber R, and Blanchard V. Sialic acid methylation refines capillary electrophoresis laser-induced fluorescence analyses of immunoglobulin G N-glycans of ovarian cancer patients. *Electrophoresis* 2014; 35(7):1025-1031. PMID: 24812685.
29. Winkler A, Berger M, and Ehlers M. Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies [v1; ref status: indexed, <http://f1000r.es/1fg>]. *F1000Research* 2013; 2:169. doi: 10.12688/f1000research.2-169.v1. PMID: 24358898.
30. Collin M, and Ehlers M. The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies. *Exp Dermatol* 2013; 22(8):511-514. Review. doi: 10.1111/exd.12171. PMID: 23808883.
31. Hess C, Winkler A, Lorenz AK, Holecska V, Blanchard V, Eiglmeier S, Schoen A-L, Bitterling J, Stoehr AD, Petzold D, Schommartz T, Mertes MMM, Schoen CT, Tiburzy B, Herrmann A, Köhl J, Manz RA, Madaio MP, Berger M, Wardemann H, and Ehlers M. T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. *J Clinical Invest* 2013; 123(9):3788-3796. doi: 10.1172/JCI65938. PMID: 23979161.
32. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, McDonald JU, Orr S, Berger M, Petzold D, Blanchard V, Winkler A, Hess C, Reid DM, Majoul IV, Strait RT, Harris NL, Köhl G, Wollin L, Ludwig R, Zillikens D, Nimmerjahn F, Finkelman FD, Brown GD, Ehlers M, and Köhl J. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. *Nat Med* 2012; 18(9):1401-1406. doi: 10.1038/nm.2862. PMID: 22922409.
33. Oefner CM, Winkler A, Hess C, Lorenz AK, Holecska V, Huxdorf M, Schommartz T, Petzold D, Bitterling J, Schoen A-L, Stoehr AD, Vu Van D, Darcan-Nikolaisen Y, Blanchard V, Schmutte I, Laumonnier Y, Ströver HA, Hegazy AN, Eiglmeier S, Schoen CT, Mertes MMM, Loddenkemper C, Löhning M, König P, Petersen A, Luger EO, Collin M, Köhl J, Hutloff A, Hamelmann E, Berger M, Wardemann H, and Ehlers M. Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. *J Allergy Clin Immunol* 2012; 129(6):1647-1655. doi: 10.1016/j.jaci.2012.02.037. PMID: 22502800.
34. Ehlers M. Glycosylation-dependent effector function of IgG antibodies. *Z. Rheumatol.* 2012; 71(9):798-800. Review. doi: 10.1007/s00393-012-1007-7. PMID: 23138557.
35. Stoehr AD, Schoen CT, Mertes MMM, Eiglmeier S, Holecska V, Lorenz AK, Schommartz T, Schoen A-L, Hess C, Winkler A, Wardemann H, and Ehlers M. TLR9 in peritoneal B-1b cells is essential for production of protective self-reactive IgM to control Th17 cells and severe autoimmunity.

J Immunol 2011; 187(6):2953-2965. doi: 10.4049/jimmunol.1003340. PMID: 21859955.

36. Tiller T, Kofer J, Kreschel C, Busse CE, Riebel S, Wickert S, Oden F, Mertes MMM, Ehlers M, and Wardemann H. Development of self-reactive germinal center B cells and plasma cells in autoimmune FcγRIIB-deficient mice. J Exp Med 2010; 207(12):2767-2778. doi: 10.1084/jem.20100171. PMID: 21078890.

37. Zamisch M, Tian L, Grenningloh R, Xiong Y, Wildt KF, Ehlers M, Ho-C, and Bosselut R. The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus. J Exp Med 2009; 206(12):2685-2699. doi: 10.1084/jem.20092024. PMID: 19917777.

38. Fischer M, and Ehlers M. Toll-like receptors in autoimmunity. The Year in Immunology 2008, Ann N Y Acad Sci 2008; 1143:21-34. Review. doi: 10.1196/annals.1443.012. PMID: 19076342.

39. Ehlers M, and Ravetch JV. Opposing effects of Toll-like receptor signals induce autoimmunity or tolerance. Trends in Immunol 2007; 28(2):74-79. Review. doi: 10.1016/j.it.2006.12.006. PMID: 17197239.

40. Wildt, KF, Sun G, Grueter B, Fischer M, Zanisch M, Ehlers M, and Bosselut R. The transcription factor Zbtb7b promotes CD4 expression by antagonizing Runx-mediated activation of the CD4 silencer. J Immunol 2007; 179(7):4405-4414. PMID: 17878336.

41. Ehlers M, Fukuyama H, McGaha H, Aderem A, and Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006; 203(3):553-561. PMID: 16492804.

42. Grueter B, Petter M, Laule-Kilian K, Egawa T, Aldrian CJ, Wuerch A, Ludwig Y, Fukuyama H, Wardemann H, Waldschuetz R, Moeroey T, Taniuchi I, Steimle V, Littman DR, and Ehlers M. Runx3 regulates integrin alphaE/CD103 and CD4 expression during development of CD4-/CD8+ T cells. J Immunol 2005; 175(3):1694-1705. PMID: 16034110. Erratum: J Immunol 2005; 175 (9):6238.

43. Dhodapkar KM, Kaufman JL, Ehlers M, Banerjee DK, Bonvini E, Koenig S, Steinman RM, Ravetch JV, and Dhodapkar MV. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A 2005; 102(8):2910-2915. PMID: 15703291.

44. Ehlers M, Laule-Kilian K, Petter M, Aldrian CJ, Grüter B, Würch A, Yoshida N, Watanabe T, Satake M, and Steimle V. Morpholino antisense oligonucleotide-mediated gene knockdown during thymocyte development reveals role for Runx3 transcription factor in CD4 silencing during development of CD4-/CD8+ thymocytes. J Immunol 2003; 171(7):3594-3604. PMID: 14500656.

45. Ehlers M, Grötzinger J, Fischer M, Klaasse Bos H, Brakenhoff, JPJ, and Rose-John S. Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation. J Interferon Cytokine Res 1996; 16(8):569-576. PMID: 8877726.

46. Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, Meyer zum Büschenfelde K.-H, and Rose-John S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996; 183(4):1399-1406. PMID: 8666898.

# THE INUM.

47. Vollmer P, Peters M, Ehlers M, Yagame H, Matsuba T, Kondo M, Yasukawa K, Meyer zum Büschenfelde K-H, and Rose-John S. Yeast expression of the cytokine receptor domain of the soluble interleukin-6-receptor. *J Immunol Methods* 1996; 199(1):47-54. PMID: 8960097.
48. Ehlers M, de Hon FD, Klaasse Bos H, Horsten U, Kurapkat G, Schmitz van De Leur H, Grötzinger J, Wollmer A, Brakenhoff JPJ, and Rose-John S. Combining two mutations of human Interleukin-6 that affect gp130 activation results in a potent Interleukin-6 receptor antagonist on human myeloma cells. *J Biol Chem* 1995; 270(14):8158-8163. PMID: 7713920.
49. de Hon FD, ten Boekel E, Herrmann J, Clement C, Ehlers M, Taga T, Yasukawa K, Ohsugi Y, Kishimoto T, Rose-John S, Wijdenes J, Kastelein R, Aarden LA, and Brakenhoff JPJ. Functional distinction of two regions of human interleukin-6 important for signal transduction via gp130. *Cytokine* 1995; 7(5):398-407. PMID: 7578977.
50. Ehlers M, Grötzinger J, de Hon FD, Müllberg J, Brakenhoff JPJ, Wollmer A, and Rose-John S. Residues 77-95 of the human interleukin-6 protein are responsible for receptor binding and residues 41-56 for signal transduction. *Ann NY Acad Sci* 1995; 762:400-402. PMID: 7668541.
51. Rose-John S, Ehlers M, Grötzinger J, and Müllberg J. The soluble interleukin-6 receptor. *Ann NY Acad Sci* 1995; 762:207-220. PMID: 7668529.
52. de Hon FD, Ehlers M, Rose-John S, Ebeling SB, Klaasse Bos H, Aarden LA, and Brakenhoff JPJ. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. *J Exp Med* 1994; 180(6):2395-2400. PMID: 7964514.
53. Ehlers M, Grötzinger J, de Hon FD, Müllberg J, Brakenhoff JPJ, Liu J, Wollmer A, and Rose-John S. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. *J Immunol* 1994; 153(4):1744-1753. PMID: 7519211.